CGON CG ONCOLOGY INC
2026Q2 · CUSIP 156944100 · Sector: Healthcare & Biotech
Funds are exiting, but the price is holding
225 funds held CGON at the end of 2026Q2, down 6 from the quarter before. Buying has faded, though the price is holding up. On the business itself, revenue over the last 12 months was $6M(YoY +1030.3%), return on equity is -21.8%. CGON has had 3 buying rushes in its history, and the price moved +45.9% on average over the six months after (that is the raw price move, not how much it beat the market by). It sits in the Healthcare & Biotech sector.
How many funds owned it, quarter by quarter
Bars = net change in institutional holders, positive (green) or negative (red). Line = total institutional holders.
What happened after each past buying rush 3 times in its history
| Quarter of the rush | How unusual then | Price, next 3 months | Price, next 6 months |
|---|---|---|---|
| 2026Q1 | Top 10% | — | — |
| 2025Q2 | Top 20% | +56.9% | +111.3% |
| 2024Q2 | Top 20% | +3.7% | -19.6% |
These are the raw price moves, not how much it beat the market by. Compare them against the market over the same months — in a strong bull market almost everything is up.
Show all the numbers (large funds, value held, options…) ▾ Collapse ▴
These are for people who want to dig. Skip them if they do not mean anything to you — the three numbers above are enough.
8,697 institutions have filed for this quarter. 13F permits late filing and a small number arrive in the weeks after the deadline, so the holder counts and changes below may tick up.
Fundamentals
Quarterly figures, revenue up to 10 years back; EPS split-adjusted, early quarters hidden when not calibrable
FCF = operating cash flow − capex, computed from SEC XBRL; banks/insurers have no standard cash-flow structure and are hidden
As of 2026-06-30 · SEC filings (XBRL)
Email me the next update
2026 Q3 holdings are due 2026-11-16. We will email you when the refreshed lists are live.